Subjective and objective outcomes of botulinum toxin type A treatment in vestibulodynia: pilot data.

Subjective and objective outcomes of botulinum toxin type A treatment in vestibulodynia: pilot data. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Subjective and objective outcomes of botulinum toxin type A treatment in vestibulodynia: pilot data. Abstract Text:

Candace S Brown,Howard I Glazer,Val Vogt,Daniel Menkes,Gloria Bachmann,

OBJECTIVE: To collect pilot data on the efficacy of intramuscular botulinum toxin type A (BTX/A) injection into the levator ani muscles to relieve coital pain, reduce pelvic floor tension and instability, and reduce vestibular hyperalgesia in vestibulodynia. STUDY DESIGN: Two subjects meeting diagnostic criteria for vestibulodynia were treated with 20 units and 40 units of BTX/A at 12-week intervals. Outcomes included a visual analogue scale (VAS), weekly coital pain diaries, surface electromyography (sEMG) and a vulvar algesiometer. RESULTS: BTX/A modestly reduced coital pain in 1 patient and was ineffective in the other. Pelvic floor hypertonicity and variability were markedly reduced in both patients, but negligible changes occurred in vestibular hyperalgesia. The patient with greater pelvic floor tension had more of a reduction in diary-rated coital pain 2 weeks after the injection (29% vs. 9%) and on the VAS at 12 weeks (15% vs. 3%). CONCLUSION: BTX/A injections may be effective in reducing coital pain in vestibulodynia with levator ani tenderness but have little effect on vestibular allodynia. The relationship between pelvic floor hypertonicity and decreased coital pain suggests that vestibulodynia may be a variant of chronic regional pain syndrome. The dose and volume of BTX/A injected may be related to the degree of relief.

Subjective and objective outcomes of botulinum toxin type A treatment in vestibulodynia: pilot data. Publishing Authors By Initials

CS Brown,HI Glazer,V Vogt,D Menkes,G Bachmann,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Subjective and objective outcomes of botulinum toxin type A treatment in vestibulodynia: pilot data. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: The Journal of reproductive medicine

VOLUME: 51

Page Numbers: 635-41

Journal Abbreviation:

ISSN: 0024-7758

DAY: 3

MONTH: Aug

YEAR: 2006

Subjective and objective outcomes of botulinum toxin type A treatment in vestibulodynia: pilot data. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 173343

Subjective and objective outcomes of botulinum toxin type A treatment in vestibulodynia: pilot data. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Subjective and objective outcomes of botulinum toxin type A treatment in vestibulodynia: pilot data. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Subjective and objective outcomes of botulinum toxin type A treatment in vestibulodynia: pilot data.

AFFILIATION: Department of Pharmacy, University of Tennessee Health Science Center, Memphis, USA. csbrown@utmem.edu

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Reprod Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Subjective and objective outcomes of botulinum toxin type A treatment in vestibulodynia: pilot data Related Publications

• Abrogation of protein uptake through megalin-deficient proximal tubules does not safeguard against tubulointerstitial injury.
• Are there modulated Electromagnetic Field Effects on Human Conscious Perception during Attentional Blink Test?
• Cognitive-behavioural treatment for weight loss in primary care: a prospective study.
• Different effects of the two types of spatial pre-cueing: what precisely is "attention" in Di Lollo's and Enns' substitution masking theory?
• Dihydroxydocosahexaenoic acids of the neuroprotectin D family: synthesis, structure, and inhibition of human 5-lipoxygenase.
• Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design.
• Expression of Prenylated Rab Acceptor 1 Domain Family, Member 2 (PRAF2) in Neuroblastoma: Correlation with Clinical Features, Cellular Localization, and Cerulenin-Mediated Apoptosis Regulation.
• Geographic distribution and recombination of genomic fragments on the short arm of chromosome 2 of Arabidopsis thaliana.
• HIV risk among long-haul truckers in the USA.
• Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites.
• Mitochondrial DNA variation of a natural population of Gyrodactylus thymalli (Monogenea) from the type locality River Hnilec, Slovakia.
• Oral purified bacterial extracts in acute respiratory tract infections in childhood: a systematic quantitative review.
• Pattern recognition by B cells: the role of antigen repetitiveness versus Toll-like receptors.
• Pentothal-sodium requirement in man; report of case.
• Phosphonopeptide K-26 biosynthetic intermediates in Astrosporangium hypotensionis.
• Reply: Body weight in patients with Parkinson's disease.
• Subjective and objective outcomes of botulinum toxin type A treatment in vestibulodynia: pilot data.
• Synthesis of nucleotide analogues by a promiscuous phosphoribosyltransferase.
• Targeting osteoporosis and rheumatoid arthritis by active vaccination against RANKL.
• Vasopressin V2 receptor expression along rat, mouse, and human renal epithelia with focus on TAL.
• When beauty breaks down: investigation of the effect of spatial quantisation on aesthetic evaluation of facial images.
• Will the circle be unbroken: a history of the U.S. National Ambient Air Quality Standards.
• ["... The better to see you with"--phothodynamic diagnostic in superficial bladder cancer]
• [Diagnosis: meanders and shortcuts]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]